ArticleFrontiers in cell and developmental biology2020
Characterization of
Article in Frontiers in cell and developmental biology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 21 citations in OpenAlex.
- Targeted mutagenesis and base editing using engineeredPlant biotechnology (Tokyo, Japan) · 2026Article
- CRISPR-Cas technologies: Emerging tools from research to clinical application.Journal of microbiology (Seoul, Korea) · 2025Review
- Recent advances in therapeutic gene-editing technologies.Molecular therapy : the journal of the American Society of Gene Therapy · 2025Review
- CRISPR technology in human diseases.MedComm · 2024Review
- Structure and engineering of Brevibacillus laterosporus Cas9.Communications biology · 2024Article
- Phage-assisted evolution of compact Cas9 variants targeting a simple NNG PAM.Nature chemical biology · 2024Article
- Seeing the Future: A Review of Ocular Therapy.Bioengineering (Basel, Switzerland) · 2024Review
- Efficient plant genome engineering using a probiotic sourced CRISPR-Cas9 system.Nature communications · 2023Article
- The applications of CRISPR/Cas-mediated genome editing in genetic hearing loss.Cell & bioscience · 2023Review
- Genome editing with natural and engineered CjCas9 orthologs.Molecular therapy : the journal of the American Society of Gene Therapy · 2023Article
- A highly specific CRISPR-Cas12j nuclease enables allele-specific genome editing.Science advances · 2023Article
- Identification of SaCas9 orthologs containing a conserved serine residue that determines simple NNGG PAM recognition.PLoS biology · 2022Article
- Article
- Two high-fidelity variants: efSaCas9 and SaCas9-HF, which one is better?Gene therapy · 2022Article
- Compact SchCas9 Recognizes the Simple NNGR PAM.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2022Article
- Employing CRISPR/Cas Technology for the Improvement of Potato and Other Tuber Crops.Frontiers in plant science · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Compact CRISPR/Cas9 systems that can be delivered by AAV for
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.